Category: Cancer

Cancer

Twist Bioscience Launches Custom MRD Panels for Cancer Assay Development

The new platform offers custom panel manufacturing in as little as one day to support development of tumor-informed MRD assays.

Cancer

Labcorp and Waters Partner to Offer Extended-Genotype BD Onclarity HPV Assay Nationwide

Labcorp plans to offer the HPV test through clinician-collected and self-collected screening options beginning in late 2026, providing extended genotyping to help guide cervical cancer risk assessment.

Cancer

AI Analysis of Pathology Slides Shows Promise for Guiding Lung Cancer Biomarker Testing

A study of more than 60,000 lung cancer cases found that AI could predict the presence of 12 biomarkers with more than 80% sensitivity, potentially helping laboratories prioritize additional testing.

Real-World Evidence from Over 2,000 Patients Supports Routine Blood-Based Lung Nodule Testing

Oct 15, 2026 | Lung Cancer

Biodesix presented data at CHEST 2026 from over 2,000 patients in the CLARIFY study, highlighting how Nodify Lung blood-based testing integrates with PET imaging to improve follow-up adherence for pulmonary nodules.

Why Better Cancer Detection May Depend on Measuring Biomarkers Differently—Not Finding New Ones

Oct 15, 2026 | Cancer

Analyzing the structure of existing biomarkers could reveal new information about cancer, helping laboratories deliver more accurate and clinically useful results.

TissueCypher Identifies Risk of Barrett’s Esophagus Progression Beyond Biopsy Alone

Oct 13, 2026 | Cancer, Histology

Castle Biosciences’ new data presented at ACG 2026 show the TissueCypher test offers objective risk stratification for Barrett’s esophagus progression, providing information beyond standard histopathology.

University Spin-Out Launches to Commercialize Adrenal Cancer and Hormone Disorder Tests

Oct 9, 2026 | Cancer, Diabetes & Metabolic Diseases, Mass Spectrometry

IMS Solutions, a University of Birmingham and Imperial College London spin-out, has raised £1.1 million to commercialize mass spectrometry-based steroid biomarker tests for adrenal cancer and PMOS, with clinical validation underway.

Multi-Omics Blood Test Shows Promise for Early Detection of Three Gynecologic Cancers

Oct 9, 2026 | Cervical (HPV), Womens Health

New data show high diagnostic performance for ovarian, endometrial, and cervical cancers, with a targeted assay designed to run on existing clinical laboratory equipment.

Multi-Omic Test Predicts Radiation Therapy Benefit in Early-Stage Breast Cancer, Study Finds

Oct 9, 2026 | Breast

An independent validation study of 426 patients evaluated the assay’s ability to assess 10-year recurrence risk and identify patients more likely to benefit from radiation therapy.

10x Genomics, Fred Hutch Launch Cancer Diagnostics Research Collaboration

Oct 7, 2026 | Cancer, Leukemia, Molecular Diagnostics

10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.

Cerenome Launches Two CSF Molecular Profiling Tests for CNS Cancers

Oct 7, 2026 | Cancer, Molecular Diagnostics

Cerenome has launched two CSF-based molecular profiling tests for CNS cancers, offering DNA and RNA sequencing panels to evaluate primary, metastatic, and hematologic malignancies in the central nervous system.

Pillar Biosciences Launches 80-Gene NGS Panel for Myeloid Malignancies

Oct 6, 2026 | Cancer, Molecular Diagnostics

Pillar Biosciences has introduced the oncoReveal Myeloid v2 Panel, expanding its NGS assay from 58 to 80 genes and enhancing FLT3-ITD detection while maintaining existing laboratory workflows.

Haystack MRD Accurately Predicts Colorectal Cancer Recurrence, Study Finds

Oct 5, 2026 | Colorectal

A study found that Quest Diagnostics’ Haystack MRD ctDNA test detected colorectal cancer recurrence with up to 100% specificity, outperforming CEA testing in DYNAMIC trial patient specimens.

Urine Cell-Free RNA Test Detects Bladder Cancer and Predicts Therapy Response

Oct 5, 2026 | Cancer, Urine Analyzers

A Stanford-led study found that Resero Bio’s uRARE-seq urine cfRNA test can non-invasively detect bladder cancer, assess tumor grade, and predict therapy response in 683 patient samples.

MIT Engineers Develop Handheld Device to Collect Viable Cells for Early Cancer Detection

Oct 1, 2026 | Anatomic Pathology, Cancer, Lab Equipment

Using microfluidic shear stress, the system detaches living cells from excised tissue to support pathology workflows and downstream diagnostic testing.

Astrin Biosciences Expands Access to Certitude Breast Cancer Blood Test to 48 States

Oct 1, 2026 | Breast

Astrin Biosciences has expanded access to its Certitude breast cancer blood test to 48 states through OpenLoop Health. The assay showed 92% sensitivity and 93% specificity in clinical validation.

Project HOPE Launches Wisconsin Initiative to Expand Prostate Cancer Screening

Oct 1, 2026 | Prostate

Project HOPE, funded by The Labcorp Charitable Foundation, has launched a two-year Madison, Wisconsin, initiative with local clinics to expand PSA testing and prostate cancer care for uninsured men facing access barriers.

Abbott Launches SimpleScreen CRC Blood Test for Colorectal Cancer Screening

Sep 30, 2026 | Colorectal

Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults, reporting 81.1% sensitivity and 90.4% specificity in a 48,000-patient study.